Details
Stereochemistry | ACHIRAL |
Molecular Formula | C9H11ClN4O2 |
Molecular Weight | 242.662 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
ClC1=C(CN2CCCC2=N)NC(=O)NC1=O
InChI
InChIKey=QQHMKNYGKVVGCZ-UHFFFAOYSA-N
InChI=1S/C9H11ClN4O2/c10-7-5(12-9(16)13-8(7)15)4-14-3-1-2-6(14)11/h11H,1-4H2,(H2,12,13,15,16)
Molecular Formula | C9H11ClN4O2 |
Molecular Weight | 242.662 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 01:41:50 UTC 2023
by
admin
on
Sat Dec 16 01:41:50 UTC 2023
|
Record UNII |
NGO10K751P
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
564116
Created by
admin on Sat Dec 16 01:41:50 UTC 2023 , Edited by admin on Sat Dec 16 01:41:50 UTC 2023
|
||
|
NCI_THESAURUS |
C129825
Created by
admin on Sat Dec 16 01:41:50 UTC 2023 , Edited by admin on Sat Dec 16 01:41:50 UTC 2023
|
||
|
NDF-RT |
N0000191870
Created by
admin on Sat Dec 16 01:41:50 UTC 2023 , Edited by admin on Sat Dec 16 01:41:50 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
NGO10K751P
Created by
admin on Sat Dec 16 01:41:50 UTC 2023 , Edited by admin on Sat Dec 16 01:41:50 UTC 2023
|
PRIMARY | |||
|
8696
Created by
admin on Sat Dec 16 01:41:50 UTC 2023 , Edited by admin on Sat Dec 16 01:41:50 UTC 2023
|
PRIMARY | |||
|
183204-74-2
Created by
admin on Sat Dec 16 01:41:50 UTC 2023 , Edited by admin on Sat Dec 16 01:41:50 UTC 2023
|
PRIMARY | |||
|
CHEMBL235668
Created by
admin on Sat Dec 16 01:41:50 UTC 2023 , Edited by admin on Sat Dec 16 01:41:50 UTC 2023
|
PRIMARY | |||
|
C152646
Created by
admin on Sat Dec 16 01:41:50 UTC 2023 , Edited by admin on Sat Dec 16 01:41:50 UTC 2023
|
PRIMARY | |||
|
4893
Created by
admin on Sat Dec 16 01:41:50 UTC 2023 , Edited by admin on Sat Dec 16 01:41:50 UTC 2023
|
PRIMARY | |||
|
DB09343
Created by
admin on Sat Dec 16 01:41:50 UTC 2023 , Edited by admin on Sat Dec 16 01:41:50 UTC 2023
|
PRIMARY | |||
|
N0000191869
Created by
admin on Sat Dec 16 01:41:50 UTC 2023 , Edited by admin on Sat Dec 16 01:41:50 UTC 2023
|
PRIMARY | Thymidine Phosphorylase Inhibitors [MoA] | ||
|
NGO10K751P
Created by
admin on Sat Dec 16 01:41:50 UTC 2023 , Edited by admin on Sat Dec 16 01:41:50 UTC 2023
|
PRIMARY | |||
|
DTXSID601025833
Created by
admin on Sat Dec 16 01:41:50 UTC 2023 , Edited by admin on Sat Dec 16 01:41:50 UTC 2023
|
PRIMARY | |||
|
1670304
Created by
admin on Sat Dec 16 01:41:50 UTC 2023 , Edited by admin on Sat Dec 16 01:41:50 UTC 2023
|
PRIMARY | RxNorm | ||
|
90879
Created by
admin on Sat Dec 16 01:41:50 UTC 2023 , Edited by admin on Sat Dec 16 01:41:50 UTC 2023
|
PRIMARY | |||
|
SUB174128
Created by
admin on Sat Dec 16 01:41:50 UTC 2023 , Edited by admin on Sat Dec 16 01:41:50 UTC 2023
|
PRIMARY | |||
|
Tipiracil
Created by
admin on Sat Dec 16 01:41:50 UTC 2023 , Edited by admin on Sat Dec 16 01:41:50 UTC 2023
|
PRIMARY | |||
|
6323266
Created by
admin on Sat Dec 16 01:41:50 UTC 2023 , Edited by admin on Sat Dec 16 01:41:50 UTC 2023
|
PRIMARY | |||
|
100000160943
Created by
admin on Sat Dec 16 01:41:50 UTC 2023 , Edited by admin on Sat Dec 16 01:41:50 UTC 2023
|
PRIMARY | |||
|
9500
Created by
admin on Sat Dec 16 01:41:50 UTC 2023 , Edited by admin on Sat Dec 16 01:41:50 UTC 2023
|
PRIMARY | |||
|
BC-15
Created by
admin on Sat Dec 16 01:41:50 UTC 2023 , Edited by admin on Sat Dec 16 01:41:50 UTC 2023
|
PRIMARY | |||
|
m11862
Created by
admin on Sat Dec 16 01:41:50 UTC 2023 , Edited by admin on Sat Dec 16 01:41:50 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
TARGET -> INHIBITOR | |||
|
BINDER->LIGAND |
The in vitro protein binding in human plasma is below 8% for tipiracil.
BINDING
|
||
|
EXCRETED UNCHANGED |
URINE
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Volume of Distribution | PHARMACOKINETIC |
|
SINGLE DOSE ADMINISTRATION |
|
||
Biological Half-life | PHARMACOKINETIC |
|
SINGLE DOSE ADMINISTRATION |
|
||